# US 2003/0229035 A1 · Method of restoring ciliated cell motility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229035 A1
- Document ID: US20030229035A1
- Status: Published application
- Kind: A1
- Application number: 09/967,399
- Filed: 2001-09-28
- Published: 2003-12-11
- Earliest claimed: 2001-09-28
- Inventors: Ram K. Menon; Mark A. Sperling; Chunxia Lu; Selma Witchel; John Kasik
- Web page: https://patentgrep.com/patent/US20030229035A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/62: Insulins
- A01K 2217/075: inducing loss of function, i.e. knock out
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates to a novel gene from the insulin family, Insl6, which expresses a protein restoring motility in ciliated cells. The proteins of the insulin family play essential roles in pleiotropic physiological processes affecting metabolism, growth, and reproduction. A new member of the insulin family named Insl6 is disclosed playing an essential role in ciliated cell activity. Insl6 plays an essential role in spermatocyte function. Thus, the Insl6 gene and its protein product are useful in the treatment of infertility caused by the loss of spermatocyte motility. A method of modulating male fertility is disclosed.

## Claims

### Claim 1

A method for modulating male fertility in a male subject comprising regulating the in vivo expression of an INSL6 gene of SEQ ID No. 3.

### Claim 2 (depends on 1)

The method of claim 1 comprising administering to said male subject a composition comprising nucleic acids complementary to a coding strand of a cDNA encoding the INSL6 protein of SEQ ID No. 4 for regulating the expression of the INSL6 gene of SEQ ID No. 3 to regulate in vivo expression of the INSL6 gene of SEQ ID No. 3.

### Claim 3 (depends on 2)

The method of claim 2 wherein the complementary nucleic acids comprise nucleic acid analogs effecting nascent transcript termination.

### Claim 4 (depends on 2)

The method of claim 2 wherein the in vivo expression of INSL6 gene is regulated by administering an effective amount of a repressor of the INSL6 gene.

### Claim 5 (depends on 2)

The method of claim 2 wherein the in vivo expression of INSL6 gene is regulated by administering an effective amount of a promoter of the INSL6 gene.

### Claim 6

A method for enhancing fertility of a male subject comprising the steps of administering an effective amount of Insl6 protein of SEQ ID No. 4 to the subject's sperm during in vitro fertilization to improve capacitance of the sperm.

### Claim 7

A method for restoring sperm motility of a male subject comprising administering an effective amount of Insl6 protein of SEQ ID No. 4 to the subject's sperm during in vitro fertilization.

### Claim 8

A method for promoting development in a male embryo comprising delivering to said male embryo an effective amount of a vector comprising a nucleic acid encoding an Insl6 protein or a protein having substantial homology to the protein of SEQ ID No. 4 to induce expression of the INSL6 protein of SEQ ID No. 4.

### Claim 9 (depends on 1)

The method of claim 1 wherein the vector comprising the nucleic acid encoding the INSL6 protein of SEQ ID No. 4 is delivered to the testis of said male embryo.

### Claim 10 (depends on 1)

The method of claim 1 wherein the vector comprising the nucleic acid encoding the INSL6 protein of SEQ ID No. 4 is delivered to the germ cells of said embryo.

### Claim 11

A method for regulating levels of INSL6 protein of SEQ ID No. 4 comprising the step of regulating the degradation of INSL6 protein.

### Claim 12

A method for regulating levels of INSL6 protein of SEQ ID No. 4 comprising the step of enhancing synthesis of INSL6 protein.

### Claim 13

A composition for modulating male fertility comprising an effective amount of a protein of SEQ ID. No. 2 encoded by an INSL6 nucleic acid of SEQ ID No. 3, and a pharmaceutical carrier wherein said protein is incorporated into said pharmaceutical carrier.

### Claim 14

A composition for modulating male fertility comprising an effective amount of a substance selected from the group consisting of a repressor of the INSL6 gene, a promoter of the INSL6 gene, a nucleic acid complementary to the cDNA of INSL6 gene, and a nascent-transcript-terminating nucleic acid complementary to the INSL6 gene, and a pharmaceutically suitable carrier.

### Claim 15 (depends on 14)

The composition of claim 14 wherein the nucleic acid complementary to the cDNA of INSL6 gene is an anti-sense nucleic acid.

### Claim 16

An isolated and purified expression vector comprising a control nucleic acid sequence operatively linked to an isolated and purified nucleic acid insert encoding a protein substantially identical to the INSL6 protein of SEQ ID No. 4.

### Claim 17 (depends on 16)

The expression vector of claim 16 wherein the control sequence is a promoter enhancing expression of the insert.

### Claim 18 (depends on 17)

The expression vector of claim 17 wherein the control sequence is a repressor suppressing expression of the insert.

### Claim 19 (depends on 17)

The expression vector of claim 17 wherein the control sequence is modulated by a control molecule selected from a promoter and a repressor.

### Claim 20

A stably transformed cell line stably expressing a substantially identical protein to a INSL6 protein of SEQ ID No. 4.

### Claim 21 (depends on 20)

The cell line of claim 20 wherein the transformation is by transfection with a vector comprising an isolated and purified nucleic acid encoding a protein substantially identical to an INSL6 protein of SEQ ID. No. 4.

### Claim 22 (depends on 20)

The cell line of claim 20 wherein the cell line is a mammalian cell line.

### Claim 23 (depends on 22)

The cell line of claim 22 wherein the cell line is a mouse cell line.

### Claim 24 (depends on 22)

The cell line of claim 22 wherein the cell line is a human cell line.

### Claim 25 (depends on 22)

The cell line of claim 22 wherein the cell line is an insect cell line.

### Claim 26

A method for modulating male fertility comprising mutating the INSL6 gene of SEQ ID No. 3 at nucleotide number 22 whereby codon number 8 is changed from a serine-encoding codon to a threonine-encoding codon.

### Claim 27 (depends on 26)

The method of claim 26 wherein the mutating step comprises site-directed mutagenesis of the INSL6 gene of SEQ ID No. 3.

### Claim 28 (depends on 26)

The method of claim 26 wherein the mutating step comprises anti-sense control of expression of the INSL6 gene of SEQ ID No. 3.

### Claim 29 (depends on 26)

The method of claim 26 wherein the mutating step is performed in vivo. 52.

### Claim 30

The method for modulating male infertility comprising mutating the INSL6 gene of SEQ ID No. 3 at nucleotide number 22 whereby codon number 8 is changed from a theonine-encoding codon to a serine-encoding codon.

### Claim 31 (depends on 30)

The method of claim 30 wherein the mutating step comprises site-directed mutagenesis of the INSL6 gene of SEQ ID No. 3.

### Claim 32 (depends on 30)

The method of claim 30 wherein the mutating step comprises anti-sense control of expression of the INSL6 gene of SEQ ID No. 3.

### Claim 33

An isolated and purified antibody or fragment thereof which specifically binds to a polypeptide of SEQ ID No. 4.

### Claim 34 (depends on 33)

The antibody or fragment thereof of claim 33 wherein said antibody is a polyclonal antibody.

### Claim 35 (depends on 33)

The antibody or fragment thereof of claim 33 wherein said antibody is a monoclonal antibody.

### Claim 36 (depends on 35)

A hybridoma cell line which produces the monoclonal antibody or fragment thereof of claim 35.

### Claim 37

An isolated and purified antibody or fragment thereof which specifically binds to a polypeptide of SEQ ID No.2.

### Claim 38 (depends on 33)

A kit comprising (a) the antibody or fragment thereof of claim 33 and (b) a detection reagent to detect the presence of a specifically bound antibody.

### Claim 39 (depends on 33)

A composition comprising the antibody or fragment thereof of claim 33 and a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 40 (depends on 38)

The kit of claim 38 wherein said detection reagent is a radioisotope, affinity label, enzymatic label, fluorescent label, or paramagnetic label.

### Claim 41 (depends on 33)

A method of detecting the presence of an INSL6 polypeptide having the amino acid sequence of SEQ ID No. 4 or a fragment thereof in a cell, tissue, or fluid sample, comprising:
(a) contacting said cell, tissue, or fluid sample with an antibody or fragment of claim 33 under conditions that allow the formation of an antibody/polypeptide complex, and
(b) detecting the presence of an antibody polypeptide complex, wherein the presence of the antibody/polypeptide complex indicates the presence of an INSL6 polypeptide.

### Claim 42

A method of modulating male fertility comprising modulating cyclic-AMP levels to modulate INSL6 activity in sperm cells.

### Claim 43

A method for modulating male fertility comprising modulating a proteasome pathway to modulate INSL6 activity.

### Claim 44 (depends on 43)

The method of claim 43 wherein the proteasome pathway is modulated in vivo.

### Claim 45 (depends on 43)

The method of claim 43 wherein the proteasome pathway is modulated in vitro.

### Claim 46 (depends on 42)

The method of claim 42 wherein the cyclic-AMP level is modulated in vivo.

### Claim 47 (depends on 42)

The method of claim 42 wherein the cyclic-AMP is modulated in sperm cells in vitro.

### Claim 48

A method of diagnosing a mutation or deletion in a the INSL6 sequence of a subject comprising determining allelic homozygocity or heterozygocity of said subjects INSL6 by hybridizing in a Southern blot with marker probe selected from the group consisting of D9S251, D9S248, D9S256, DS1686, D9S1873, D9S1792, and D9S1858.

### Claim 49

A method for modulating male fertility in a male subject comprising regulating the in vivo expression of an insulin 6 gene.

### Claim 50 (depends on 49)

The method of claim 49 wherein the in vivo expression of the insulin 6 gene is regulated by administering an effective amount of a promoter of the insulin 6 gene.
